血管内皮抑素治疗消化道晚期肿瘤的临床疗效观察  

The clinical RCT about endostar injection on advanced gastrointestinal cancer

作　　者：陈音[1,2] 钟美佐[1] 陆明[2] 林燕[2] 邓皖利[2] 吴涛[2] 马金丽[2] 

机构地区：[1]中南大学湘雅医学院第一附属医院,湖南长沙410013 [2]新疆医科大学第四附属医院肿瘤科,新疆乌鲁木齐830000

出　　处：《实用临床医药杂志》2011年第7期21-23,共3页Journal of Clinical Medicine in Practice

摘　　要：目的对比研究血管内皮抑素(恩度)注射液治疗消化道晚期肿瘤的疗效及安全性。方法 32例消化道晚期肿瘤患者分为治疗组(n=16)及单纯对照组(n=16)。观察有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)及不良反应。结果治疗组的RR为56.3%,CBR为87.5%,TTP为4.6个月。对照组RR为18.8%,CBR为50%,TTP为3.4个月。两组患者的RR、CBR、TTP的差异均有统计学意义(P<0 05)。两组患者QOL差异无统计学意义。结论消化道肿瘤患者化疗方案中联合恩度注射液治疗具有更好的疗效和安全性。Objective To observe the efficacy and safety of endostar injection on advanced gastrointestinal cancer.Methods Thirty-two advanced gastrointestinal cancer patients were randomly divided into two groups,treatment group（n = 16） and control group（n = 16） respectively. The response rate（RR）,the clinical benefit rate（CBR）,time of tumor progression（TTP） and the quality of life（QOL） were observed.Results The RR of treatment group was 56.3%,the CBR was 87.5%,and TTP was 4.6 months.Meanwhile,the RR of the control group was 18.8%,the CBR was 50.0%,and the TTP was 3.4 months.The difference of RR,CBR and TTP of the two groups was statistically significant（P0.05）.The QOL of the two groups was statistically insignificant. Conclusion The endostar injection combined with chemistry is more effective and safer.

关 键 词：消化道肿瘤 晚期 化疗 血管内皮抑素 抗肿瘤血管形成 

分 类 号：R730.5[医药卫生—肿瘤]